A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...

Peptide conjugation techniques are advancing CNS delivery of oligonucleotides, addressing blood-brain barrier challenges and improving therapeutic outcomes.

In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T cells directly within the body, bypassing the weeks-long ex vivo ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...

Abstract Cancer progression involves cell adhesion molecules (CAMs), which facilitate the recruitment of leukocytes and metastatic tumor cells to ...